" class="no-js "lang="en-US"> Shyam Natarajan - Medtech Alert
Wednesday, August 27, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Shyam Natarajan

Shyam Natarajan

About Shyam Natarajan

Focused on improving clinical outcomes and patient care in urology and beyond.

Leading a clinical-stage AI healthcare startup that is creating a more personalized future of prostate cancer care. Previously led an NIH-funded lab focusing on image-guided cancer interventions at UCLA with a background in software engineering.

Related Story

Fundraising

 Avenda Health Raises $10M in Series B

Avenda Health Raises $10M in Series B, Innovating Detection and Treatment for Prostate Cancer Care

August 26 2022

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, today […]